Northvale, New Jersey – ADM Tronics Unlimited Inc. officials announced in a recent press release that the company has completed development and engineering to bring the Alvio Respiratory Therapy platform to production-ready status. All components are in place for the initial 100-unit production run being assembled and Alvio devices from this run will be deployed for patient and clinic testing.
Announced nearly a year ago, ADMT entered into an agreement with QoL Devices Inc., for development, regulatory activities, and manufacturing of the Alvio platform targeted for use in non-regulated respiratory training applications as well as for medical respiratory indications.
Bez Arkush, founder and President of QoL commented that, “this is a significant milestone for our respiratory technology that has the potential to help millions of people.”
The initial Alvio production units are slated for user and clinic testing under the direction of Dr. Bruce Johnson who has dedicated his research to improving treatment of patients with pulmonary conditions.
ADMT has developed and engineered all the supply chain components required to manufacture Alvio devices in ADMT's FDA-registered medical device manufacturing facility. QoL and ADMT plan to first introduce a non-regulated version of Alvio for sale to consumers for breathing training, while preparing submission to FDA for clearance of Alvio for medical applications in the U.S. and for CE marking for Europe.
Arkush says the Alvio, the a fully integrated respiratory therapy platform, mobile connected, respiratory sensor and trainer, is a device that is “positioned to disrupt the $5+ billion U.S. and the $6+ billion international respiratory therapy markets.”
ADMT President Andre' DiMino notes that the Alivo “has the potential to help so many with debilitating respiratory problems. It is especially gratifying to me to be bringing forward a technology that can help children with asthma.”
ADMT is an equity holder in QoL.